Cairn Diagnostics is a specialized, innovative technology company focused on pioneering, manufacturing, validating and obtaining FDA-approvals for novel breath tests intended for routine use in diagnostic medicine.
Cairn develops orally administered substrates labeled with a safe, non-radioactive stable isotope of carbon, carbon-13 (13C) to generate diagnostically accurate, safe and conveniently administered breath tests. Commercially available tests are non-invasive, non-radioactive, office based, standardized and FDA-approved.
Cairn serves community-based practices and partners with university-based researchers, medical device and pharmaceutical companies.
Cairn’s best-known products are the original 13C-Urea Breath Test (“UBT”) for diagnosis and confirmation of clearance of H. pylori infection and the new 13C-Spirulina Gastric Emptying Breath Test (“GEBT”) for measuring the rate of solid phase gastric emptying and identifying gastroparesis.